Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> TGF-β / Smad Signaling

TGF-β / Smad Signaling

Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that regulates proliferation, migration, differentiation, and survival of many different cell types. Deletion or mutation of different members of the TGF-β family have been shown to cause vascular remodeling defect and absence of mural cell formation, leading to embryonic lethality or severe vascular disorders. TGF-β induces smooth muscle differentiation via Notch or SMAD2 and SMAD3 signaling in ES cells or in a neural crest stem cell line. TGF-β binds to TGF-βRI and to induce phosphorylation of SMAD2/3, thereby inhibiting proliferation, tube formation, and migration of endothelial cells (ECs).

TGF-β is a pluripotent cytokine with dual tumour-suppressive and tumour-promoting effects. TGF-β induces the epithelial-to-mesenchymal transition (EMT) leading to increased cell plasticity at the onset of cancer cell invasion and metastasis.

Targets for  TGF-β / Smad Signaling

Products for  TGF-β / Smad Signaling

  1. Cat.No. Product Name Information
  2. GC12560 Dorsomorphin (Compound C) 2HCl

    BML-275 2HCl,Compound C 2HCl

     IC50: Dorsomorphin inhibited BMP4-induced phosphorylation of BMP-responsive SMADs in a dose-dependent manner (half maximal inhibitory concentration (IC50) =0.47 mM). Dorsomorphin (Compound C) 2HCl Chemical Structure
  3. GC35897 DPH A potent cell permeable c-Abl activator DPH Chemical Structure
  4. GC73653 DT-6 DT-6 is an effective TGF-β1 inhibitor. DT-6 Chemical Structure
  5. GC90543 EGFR Peptide (human, mouse) (myristoylated) (trifluoroacetate salt)

    A PKC inhibitor

     EGFR Peptide (human, mouse) (myristoylated) (trifluoroacetate salt) Chemical Structure
  6. GC69052 Elezanumab

    Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab effectively inhibits RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, with an IC50 of approximately 97 pM. Elezanumab promotes neuronal regeneration and neuroprotection in models of nerve injury and demyelination by binding to the N-terminal of RGMa, blocking BMP signaling, and lacking cross-reactivity with RGMc. Elezanumab has activity in promoting neuronal regeneration and neuroprotection without affecting iron metabolism.

     Elezanumab Chemical Structure
  7. GC32914 EMT inhibitor-1 EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities. EMT inhibitor-1 Chemical Structure
  8. GC11499 Enzastaurin (LY317615)

    LY317615

     Enzastaurin (LY317615) (LY317615) is a potent and selective PKCβ inhibitor with an IC50 of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε. Enzastaurin (LY317615) Chemical Structure
  9. GC65329 EW-7195 EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung. EW-7195 Chemical Structure
  10. GC13354 EW-7197

    Vactosertib, TEW-7197

     EW-7197 (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC50 of 12.9 nM. EW-7197 also inhibits ALK2 and ALK4 (IC50 of 17.3 nM) at nanomolar concentrations. EW-7197 has potently antimetastatic activity and anticancer effect. EW-7197 Chemical Structure
  11. GC13869 Fasudil Fasudil (HA-1077; AT877) is a non-specific RhoA/ROCK inhibitor with a Ki of 0.33μM and an IC50 of 0.158μM for ROCK1, and IC50 of 4.58μM, 12.30μM, and 1.650μM for ROCK2, PKA, PKC, and PKG, respectively. Fasudil Chemical Structure
  12. GC14289 Fasudil (HA-1077) HCl Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil (HA-1077) HCl is also a potent Ca2+ channel antagonist and vasodilator. Fasudil (HA-1077) HCl Chemical Structure
  13. GC32867 Flumatinib (HHGV678)

    HH-GV-678

     Flumatinib (HHGV678) (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib (HHGV678) inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively. Flumatinib (HHGV678) Chemical Structure
  14. GC13914 Flumatinib mesylate PDGRFβ inhibitor Flumatinib mesylate Chemical Structure
  15. GC12027 FR 236924

    FR 236924

     FR 236924 (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. FR 236924 Chemical Structure
  16. GC65539 Fresolimumab Fresolimumab is a high-affinity humanized monoclonal antibody that binds to and inhibits all isoforms of the protein transforming growth factor β (TGFβ). The Kd values of Fresolimumab for TGFβ1, TGFβ2, and TGFβ3 are 1.7±0.6nM, 3.0±1.2nM, and 2.0±1.2nM, respectively. Fresolimumab Chemical Structure
  17. GC15431 GF 109203X (Bisindolylmaleimide I)

    Gö 6850;Bisindolylmaleimide I

     GF 109203X is a selective inhibitor of protein kinase C, selective for the α and β1 isoforms with IC50 values of 0.0084, 0.0180, 0.210, 0.132, and 5.8μM for α, β1, δ, ε and ζ isoforms of protein kinase C respectively. GF 109203X (Bisindolylmaleimide I) Chemical Structure
  18. GC36167 GMB-475 GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein. GMB-475 Chemical Structure
  19. GC10858 GNF 2

    Bcr-Abl Inhibitor

     Bcr-Abl inhibitor GNF 2 Chemical Structure
  20. GC15079 GNF 5 Bcr-Abl inhibitor GNF 5 Chemical Structure
  21. GC10607 GNF-7

    Type II Bcr-Abl inhibitor

     GNF-7 Chemical Structure
  22. GC15564 Go 6976

    Go6976;Go-6976

     PKCα/PKCβ1 inhibitor Go 6976 Chemical Structure
  23. GC16907 Go 6983

    Goe 6983;Go6983;Go-6983

     Go 6983 (GÖ 6983) is one of the bisindolylmaleimide group of PKC inhibitor compounds, Go 6983 (GÖ 6983) was able to differentiate between PKC mu and other PKC isoenzymes. Go 6983 Chemical Structure
  24. GC38791 GSK-25 GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25 Chemical Structure
  25. GC19177 GSK180736A GSK180736A is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with an IC50 of 0.77 uM. GSK180736A Chemical Structure
  26. GC17936 GSK269962A

    GSK269962A, GSK269962B

     ROCK inhibitor GSK269962A Chemical Structure
  27. GC25482 GSK269962A HCl

    GSK269962B, GSK269962, GSK 269962

     GSK269962A HCl (GSK269962B, GSK269962) is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively. GSK269962A HCl Chemical Structure
  28. GC18119 GSK429286A Selective ROCK1/ROCK2 inhibitor GSK429286A Chemical Structure
  29. GC11878 GW788388 ALK5 inhibitor,potent and selective GW788388 Chemical Structure
  30. GC10915 GZD824

    GZD824 dimesylate; HQP1351 dimesylate

     Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. GZD824 potently inhibits a broad spectrum of Bcr-Abl mutants. GZD824 strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. GZD824 has antitumor activity. GZD824 Chemical Structure
  31. GC33201 GZD856 GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4?nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity. GZD856 Chemical Structure
  32. GC36207 H-1152 H-1152 is a membrane-permeable and selective ROCK inhibitor, with a Ki value of 1.6 nM, and an IC50 value of 12 nM for ROCK2. H-1152 Chemical Structure
  33. GC36208 H-1152 dihydrochloride H-1152 dihydrochloride is a membrane-permeable and selective ROCK inhibitor, with a Ki value of 1.6 nM, and an IC50 value of 12 nM for ROCK2. H-1152 dihydrochloride Chemical Structure
  34. GC31650 Halofuginone (RU-19110) Halofuginone (RU-19110) (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone (RU-19110) Chemical Structure
  35. GC31950 Halofuginone hydrobromide (RU-19110 (hydrobromide)) Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromide (RU-19110 (hydrobromide)) Chemical Structure
  36. GC10299 Hexadecyl Methyl Glycerol

    1-O-hexadecyl-2-O-methyl-sn-Glycerol

     protein kinase C activity inhibitor Hexadecyl Methyl Glycerol Chemical Structure
  37. GC71477 HG-7-86-01 HG-7-86-01 (Compound 26) is type II tyrosine kinase inhibitor. HG-7-86-01 Chemical Structure
  38. GC15018 Hispidin protein kinase Cβ inhibitor Hispidin Chemical Structure
  39. GC64326 Hydrochlorothiazid-d2 Hydrochlorothiazid-d2 Chemical Structure
  40. GC17523 Hydrochlorothiazide

    HCTZ, NSC 53477, SU 5879

     diuretic drug of the thiazide class Hydrochlorothiazide Chemical Structure
  41. GC74190 Hydrochlorothiazide-13C6

    HCTZ-13C6

    Hydrochlorothiazide-13C6 is the 13C labeled drochlorothiazide.

     Hydrochlorothiazide-13C6 Chemical Structure
  42. GC36282 Hypocrellin A Hypocrellin A, a naturally occurring PKC inhibitor, has many biological and pharmacological properties, such as antitumour, antiviral, antibacterial, and antileishmanial activities. Hypocrellin A Chemical Structure
  43. GC15420 ICP 103 Protein kinase inhibitor ICP 103 Chemical Structure
  44. GC10314 Imatinib (STI571) Imatinib (STI571) (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib (STI571) also is an inhibitor of SARS-CoV and MERS-CoV. Imatinib (STI571) Chemical Structure
  45. GC11759 Imatinib Mesylate (STI571)

    CGP57148B, STI571

     Imatinib Mesylate (STI571) (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases. Imatinib Mesylate (STI571) Chemical Structure
  46. GC50317 IN 1130 Potent and selective inhibitor of TGF-βRI IN 1130 Chemical Structure
  47. GC32870 Ingenol ((-)-Ingenol) Ingenol ((-)-Ingenol) is a PKC activator, with a Ki of 30 μM, with antitumor activity. Ingenol ((-)-Ingenol) Chemical Structure
  48. GC61776 Ingenol 3,20-dibenzoate Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate Chemical Structure
  49. GC31656 Ingenol Mebutate (Ingenol 3-angelate)

    Ingenol Mebutate, 3Ingenyl Angelate, PEP005, Picato

     Ingenol Mebutate (Ingenol 3-angelate) is an active ingredient in Euphorbia peplus, acts as a potent PKC modulator, with Kis of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity. Ingenol Mebutate (Ingenol 3-angelate) Chemical Structure
  50. GC15148 Ionomycin calcium salt Ionomycin calcium salt is a narrow spectrum antibiotic being active against Gram-positive bacteria, which produced by the bacterium Streptomyces conglobatus. Ionomycin calcium salt Chemical Structure
  51. GC15446 Ionomycin free acid

    Ionomycin free acid is a selective and potent calcium ion carrier that acts as an active Ca2+ carrier.

     Ionomycin free acid Chemical Structure
  52. GC60210 Isosaponarin Isosaponarin is a flavone glycoside isolated from wasabi leaves. Isosaponarin Chemical Structure
  53. GC72815 Itacnosertib (hydrocholide)

    TP-0184 (hydrocholide

     Itacnosertib drocholide is an inhibitor of JAK2, ACVR1 (ALK2) and ALK5. Itacnosertib (hydrocholide) Chemical Structure
  54. GC12108 ITD 1 First selective TGFβ inhibitor ITD 1 Chemical Structure
  55. GC11362 K 252a

    SF 2370

     A protein kinase inhibitor K 252a Chemical Structure
  56. GC12817 K-115 hydrochloride dihydrate K-115 hydrochloride dihydrate (K-115) is a specific inhibitor of ROCK, with IC50s of 19 and 51 nM for ROCK2 and ROCK1, respectively. K-115 hydrochloride dihydrate Chemical Structure
  57. GC15281 K-252c

    Staurosporinone

     Protein kinase inhibitor K-252c Chemical Structure
  58. GC15567 K02288 ALK inhibitor K02288 Chemical Structure
  59. GC43993 K252b K252b is an indolocarbazole isolated from the actinomycete Nocardiopsis, first described as an inhibitor of protein kinase C. K252b Chemical Structure
  60. GC15057 Kartogenin Promote differentiation of multipotent MSCs into chondrocytes Kartogenin Chemical Structure
  61. GC71494 Kartogenin sodium Kartogenin (KGN) sodium is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin sodium Chemical Structure
  62. GC64263 Kobophenol A Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC50 of 1.81 μM and inhibits SARS-CoV-2 viral infection in cells with an EC50 of 71.6 μM. Kobophenol A Chemical Structure
  63. GC72215 KRFK TFA KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA Chemical Structure
  64. GC17346 KT 5823 A protein kinase G inhibitor KT 5823 Chemical Structure
  65. GC40770 L-erythro Sphingosine (d18:1)

    L-erythro Sphingosine, L-erythro-C18-Sphingosine

     L-erythro Sphingosine is a synthetic stereoisomer of sphingosine (d18:1). L-erythro Sphingosine (d18:1) Chemical Structure
  66. GC17815 L-threo-Sphingosine C-18

    L-threo-Sphingosine C18

     L-threo-Sphingosine C-18 is a potent MAPK inhibitor. L-threo-Sphingosine C-18 induces apoptosis and clear DNA fragmentation. L-threo-Sphingosine C-18 shows anticancer effect. L-threo-Sphingosine C-18 Chemical Structure
  67. GC16580 LDN-193189

    LDN 193189;LDN193189

     ALK inhibitor,potent and selective LDN-193189 Chemical Structure
  68. GC17035 LDN-212854 BMP receptor inhibitor,potent and selective LDN-212854 Chemical Structure
  69. GC13225 LDN-214117 potent and selective ALK2 inhibitor LDN-214117 Chemical Structure
  70. GC14931 LDN193189 Hydrochloride

    LDN 193189 hydrochloride; LDN-193189 hydrochloride

     LDN193189 Hydrochloride is a selective inhibitor of the transcriptionally active morphogenetic protein (BMP) type I receptor, a family of BMP receptors that includes activin receptor-like kinases (ALK1, ALK2, ALK3, and ALK6). LDN193189 Hydrochloride inhibits ALK2 and ALK3 with IC50 values of 5nM and 30nM, respectively. LDN193189 Hydrochloride Chemical Structure
  71. GC36433 LDN193189 Tetrahydrochloride A selective BMP type I receptor inhibitor LDN193189 Tetrahydrochloride Chemical Structure
  72. GC70857 LIMK-IN-1 LIMK-IN-1 (Compound 14) is an inhibitor of LIM-Kinase (LIMK), with IC50s of 0.5 nM and 0.9 nM for LIMK1 and LIMK2, respectively. LIMK-IN-1 Chemical Structure
  73. GC74573 Livmoniplimab

    ABBV-151; ARGX-115

     Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab Chemical Structure
  74. GC39398 LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA) LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier. LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA) Chemical Structure
  75. GC32728 LSKL, Inhibitor of Thrombospondin TSP-1 LSKL, Inhibitor of Thrombospondin TSP-1 is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin TSP-1 inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin TSP-1 suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin TSP-1 can readily crosse the blood-brain barrier. LSKL, Inhibitor of Thrombospondin TSP-1 Chemical Structure
  76. GC69412 Luspatercept

    ACE-536; luspatercept-aamt

    Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that can bind to the ligands of the transforming growth factor β superfamily. Luspatercept increases red blood cell count and promotes maturation of red blood cell precursors. Luspatercept binds with GDF11, inhibiting the Smad2/3 signaling pathway. Luspatercept can be used for research on anemia.

     Luspatercept Chemical Structure
  77. GC44094 LX7101 (hydrochloride) LX7101 is a potent inhibitor of LIM kinase (LIMK) 1 and 2 and Rho-associated kinase 1 (ROCK-1) and ROCK-2 with IC50 values of 32, 4.3, 69, and 32 nM, respectively. LX7101 (hydrochloride) Chemical Structure
  78. GC12402 LX7101 HCL LX7101 HCL is a potent inhibitor of LIMK and ROCK2 with IC50 values of 24, 1.6 and 10 nM for LIMK1, LIMK2 and ROCK2, respectively; also inhibits PKA with an IC50 less than 1 nM. LX7101 HCL Chemical Structure
  79. GC32811 LXS196

    LXS196; IDE196

     LXS196 (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. LXS196 has the potential for uveal melanoma research. LXS196 Chemical Structure
  80. GC17563 LY 333531 hydrochloride

    Ruboxistaurin

     Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). LY 333531 hydrochloride Chemical Structure
  81. GC12363 LY2109761 TβRI/II kinase inhibitor LY2109761 Chemical Structure
  82. GC18015 LY2157299

    LY-2157299;LY 2157299

     LY2157299 is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 value of 56nM. LY2157299 Chemical Structure
  83. GC19234 LY3200882 LY3200882 is a novel and highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). LY3200882 Chemical Structure
  84. GC11604 LY364947

    HTS 466284, TGFβ RI Kinase Inhibitor

    Inhibitor of TGF-β type I receptor kinase domain

     LY364947 Chemical Structure
  85. GC69418 Lyn-IN-1

    Bafetinib analog

    Lyn-IN-1 (Bafetinib analog) is a highly active dual inhibitor of Bcr-Abl and Lyn.

     Lyn-IN-1 Chemical Structure
  86. GC48345 Lyso-Monosialoganglioside GM2 (ammonium salt)

    Lysoganglioside GM2, Lyso-GM2, lyso-Monosialoganglioside GM2

     Lyso-Monosialoganglioside GM2 (ammonium salt) Chemical Structure
  87. GC30545 Malantide Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a Km of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts. Malantide is also an efficient substrate for PKC with a Km of 16 μM. Malantide Chemical Structure
  88. GC10496 Midostaurin (PKC412)

    CGP 41251

     Midostaurin (PKC412) (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin (PKC412) inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM. Midostaurin (PKC412) also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin (PKC412) shows powerful anticancer effects. Midostaurin (PKC412) Chemical Structure
  89. GC32714 Mitoxantrone (mitozantrone) Mitoxantrone is an antitumor anthrandione derivative. Mitoxantrone (mitozantrone) Chemical Structure
  90. GC14363 Mitoxantrone HCl

    NCI 301739, NSC 301739

     Mitoxantrone HCl is a potent topoisomerase II inhibitor. Mitoxantrone HCl Chemical Structure
  91. GC17582 ML347

    LDN193719

     BMP receptor inhibitor,potent and selective ML347 Chemical Structure
  92. GC65585 Mongersen

    GED-0301

     Mongersen (GED-0301) is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen Chemical Structure
  93. GC73107 Mongersen sodium

    GED-0301 sodium

     Mongersen sodium is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen sodium Chemical Structure
  94. GC74326 MPSD TFA

    MARCKS-ED TFA

     MPSD TFA (MARCKS-ED TFA) is the TFA salt form of MPSD. MPSD TFA Chemical Structure
  95. GC73234 MY-673 MY-673 is a colchicine binding site inhibitor (CBSI), that inhibits tubulin polymerization. MY-673 Chemical Structure
  96. GC63778 Myelin Basic Protein TFA

    MHP4-14 TFA

     Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein TFA Chemical Structure
  97. GC49269 Myr-ZIP

    Myristoylated-ZIP, Myristoylated Zeta-Pseudosubstrate Inhibitory Peptide, Myr-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys-Leu, Myr-SIYRRGARRWRKL-OH, Ζeta Inhibitory Peptide

     A PKMζ inhibitor Myr-ZIP Chemical Structure
  98. GC44303 N-Acetylpuromycin N-Acetylpuromycin is a non-ribotoxic form of the antibiotic puromycin that is formed in puromycin-resistant S. N-Acetylpuromycin Chemical Structure
  99. GC25662 N-Desmethyltamoxifen N-Desmethyltamoxifen, the major metabolite of Tamoxifen in humans and a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen, also is a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation. N-Desmethyltamoxifen Chemical Structure
  100. GC38931 N-Desmethyltamoxifen hydrochloride N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation. N-Desmethyltamoxifen hydrochloride Chemical Structure
  101. GC74419 N-myristoyl-RKRTLRRL N-myristoyl-RKRTLRRL inhibits binding of PKC substrates. N-myristoyl-RKRTLRRL Chemical Structure

Items 101 to 200 of 335 total

per page
  2. 1
  3. 2
  4. 3
  5. 4

Set Descending Direction